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Abstract
Corneal scarring remains a major cause of blindness world-wide, with limited treatment options, all of which have side-
effects. Here, we tested the hypothesis that topical application of Rosiglitazone, a Thiazolidinedione and ligand of
peroxisome proliferator activated receptor gamma (PPARc), can effectively block scar formation in a cat model of corneal
damage. Adult cats underwent bilateral epithelial debridement followed by excimer laser ablation of the central corneal
stroma to a depth of ,160 mm as a means of experimentally inducing a reproducible wound. Eyes were then left untreated,
or received 50 ml of either 10 mM Rosiglitazone in DMSO/Celluvisc, DMSO/Celluvisc vehicle or Celluvisc vehicle twice daily
for 2 weeks. Cellular aspects of corneal wound healing were evaluated with in vivo confocal imaging and post-mortem
immunohistochemistry for alpha smooth muscle actin (aSMA). Impacts of the wound and treatments on optical quality
were assessed using wavefront sensing and optical coherence tomography at 2, 4, 8 and 12 weeks post-operatively. In
parallel, cat corneal fibroblasts were cultured to assess the effects of Rosiglitazone on TGFb-induced aSMA expression.
Topical application of Rosiglitazone to cat eyes after injury decreased aSMA expression and haze, as well as the induction of
lower-order and residual, higher-order wavefront aberrations compared to vehicle-treated eyes. Rosiglitazone also inhibited
TGFb-induced aSMA expression in cultured corneal fibroblasts. In conclusion, Rosiglitazone effectively controlled corneal
fibrosis in vivo and in vitro, while restoring corneal thickness and optics. Its topical application may represent an effective,
new avenue for the prevention of corneal scarring with distinct advantages for pathologically thin corneas.
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Introduction
Damage to the mammalian cornea causes a rapid cellular
reaction, which attempts to heal the wound. Disruption of the
epithelial layer, basement membrane and injury to stromal
keratocytes release a range of cytokines, including transforming
growth factor b (TGFb) - probably the strongest pro-fibrotic agent
[1]. These cytokines stimulate epithelial regeneration, keratocyte
proliferation [2,3], migration [4], differentiation into fibroblasts
and myofibroblasts [3], the deposition of abnormal extracellular
matrix (ECM) proteins and the recruitment of macrophages and
other immune cells into the cornea – reviewed in [5,6]. When
stromal keratocytes are stimulated by TGFb to differentiate into
myofibroblasts [6], they assemble f-actin into stress fibers and
express a-smooth muscle actin (aSMA) [7,8], which endow them
with contractile properties [3,9]. Though undoubtedly useful for
the goal of shrinking the injury site, wound contraction in the
cornea disturbs the shape and curvature of this critical optic and its
ability to precisely focus light onto the retina. As a result, corneal
wounds increase the optical aberrations of the eye, decreasing
visual quality in a manner that is separate from (but adds to) that
caused by loss of transparency.
Loss of transparency, largely in the form of haze during corneal
wound healing results from several factors: 1) infiltration of the
cornea by inflammatory cells, 2) aSMA positive myofibroblasts,
which are less transparent than quiescent keratocytes, likely due to
their decreased crystallin synthesis [10,11], and 3) myofibroblasts
laying down ECM that is both differently organized and composed
of molecules (including collagen III, hyaluronan and other
proteoglycans low in keratan sulfate components) which are
neither part of the normal stromal ECM, nor conducive to good
corneal transparency [6,12,13,14].
Clinically, attempts to control corneal scarring have mostly
involved the use of steroids or Mitomycin C (MMC) [15,16].
While effective at decreasing myofibroblast differentiation and
haze [15,17,18,19,20,21,22,23,24], these two compounds exhibit
significant side-effects and in the case of MMC, toxicity and DNA
damage to stromal keratocytes and endothelial cells, that could
bear long-term negative consequences for ocular health [25].
Experimentally, ocular application of antibodies against TGFb
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myofibroblast differentiation, migration and corneal reflectivity
(haze) in both rabbits [26] and cats [27]. However, epithelial
healing was slowed and with application for longer than 3 days,
stromal regeneration was also blocked [27]. Here, we asked
whether small molecule pharmacologics, capable of manipulating
intracellular signaling downstream of TGFb receptor activation
might represent a better alternative to steroids, MMC and topical
application of anti-TGFb antibodies to the eye. In particular, it
would be advantageous to find a means of preventing haze and
myofibroblast differentiation, while stimulating regeneration of the
corneal stroma and epithelium, and preserving or restoring normal
ocular optics. The cat was chosen as the in vivo (and in vitro) model
in the present study because it offers several advantages over
rabbits and mice. First, the cat cornea bears strong similarities to
the human cornea: it has similar structural organization, similar
stromal and epithelial thicknesses [28], and similar corneal wound
healing responses [29,30]. Second, cats can be behaviorally
trained, allowing us to reliably measure optical correlates of
corneal wound healing repeatedly, over time, using the same
instrument (wavefront sensor), in the same state (awake-fixating)
and with the same degree of precision attained in humans
[27,31,32].
With respect to understanding intracellular signaling down-
stream of TGFb activation, this is usually studied in vitro using
‘‘wounding‘‘ models in which cultured stromal fibroblasts are
stimulated to differentiate into myofibroblasts with application of
TGFb to the culture medium [7,33,34,35]. Here, we showed that
feline corneal fibroblasts exhibit similar responses in culture as
fibroblasts from other species [7,33,34,35,36]. This is a critical
point since it is evidence from in vitro models, as well as from a few
clinical and in vivo studies in a range of body tissues
[37,38,39,40,41,42,43,44], that first revealed strong anti-fibrotic
properties for an interesting class of molecules, known a
peroxisome proliferator activated receptor gamma (PPARc)
ligands. PPARs are nuclear receptors that function as transcription
factors [37,45] and are best known for their important roles in
lipid metabolism [46,47]. Tissue distribution of PPARc2 a
subtype of PPAR - varies, with highest concentrations in adipose
tissue [48], and lower, but identifiable levels in most bodily organs
and cell types [44,49,50]. Of relevance to the present work, Saika
and colleagues showed that viral transfection and over-expression
of PPARc in the living mouse cornea reduced myofibroblast
differentiation, up-regulation of several cytokines and matrix
metalloproteases, and macrophage/monocyte invasion following
alkali burn injuries [51]. In cultured fibroblasts stimulated with
TGFc, the same authors showed that PPARc over-expression
blocked nuclear translocation of phosphorylated SMAD2, con-
firming that PPARc exerted its potent anti-fibrotic effects in
wounded corneas at least in part, by blocking signaling
downstream of TGFb receptor binding.
Since viral transfection is not yet widely practiced clinically
(although see [52]), we asked whether similarly potent anti-fibrotic
effects might be attained in wounded corneas with topical
administration of PPARc ligands/agonists – in our case,
Rosiglitazone (AvandiaH, GlaxoSmith-Kline). To date, with
respect to corneal applications, PPARc ligands have only been
used in vitro, where Pioglitazone [53], 15d-PGJ2 [54] and CDDO-
Me [54] appeared able to block TGFb-induced differentiation of
corneal fibroblasts into myofibroblasts. The present study is the
first to administer a PPARc ligand topically to the living eye
following laser ablation of the stroma. Our goal was to assess the
impact of prolonged administration of this drug on corneal
scarring, tissue regeneration and optical quality in vivo. Excimer
laser ablation was used here because its consequences for the
cornea have been well described in the clinical and experimental
literature [27,55,56,57,58]. For experimentalists, excimer laser
ablations represent an excellent means of reproducibly inducing a
corneal wound with a defined shape, size and depth, and with
predictable biological and optical consequences – reviewed in
[59,60,61].
Here we report that topical Rosiglitazone reliably and
effectively prevented myofibroblast differentiation, haze induction
and large wavefront changes after laser ablation of the cat cornea
in vivo. On the other hand, the epithelium regenerated fully within
a normal time-frame, as did most of the stroma removed by the
laser. Cell culture experiments suggested that this could be due to
a previously unreported, differential effect of Rosiglitazone on
aSMA and Collagen I expression following TGFb stimulation.
Three months post-operatively, Rosiglitazone-treated corneas




All animal procedures were conducted according to the
guidelines of the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research, and the NIH Guide for the
Care and Use of Laboratory Animals. The protocol was approved
by the University of Rochester Committee on Animal Research
(UCAR – Assurance number: A-3292-01).
In vivo Experiments
Domestic short hair cats (felis cattus) underwent bilateral laser
ablation followed by treatment with Rosiglitazone in dimethylsulf-
oxide (DMSO)/Celluvisc (RefreshCelluvisc
TM, Allergan; N=8
eyes), DMSO/Celluvisc (N=12 eyes) or Celluvisc (N=10, from
prior study from our group [27]). Details about the exact makeup
of these solutions is provided below. An additional 6 eyes from 3
cats received no eye drops after bilateral laser ablation and were
designated as ‘‘untreated’’. One Rosiglitazone-treated eye, two
Celluvisc treated eyes and two untreated eyes developed central
corneal abrasions post-operatively, largely as a result of rubbing,
and were excluded from all analysis. All other eyes underwent
imaging at 2, 4, 8 and 12 weeks post-operatively. Sets of cats were
sacrificed for histology at the 2 and 4 weeks time-points.
Remaining cats were imaged at 8 and 12 weeks, then sacrificed
at the 12 weeks time-point. Only a subgroup of the animals were
behaviorally trained for wavefront sensing, giving us 4 eyes per
treatment group in which wavefront measures were carried out at
each time-point of interest. Procedures and treatments are
summarized in Table 1.
Laser ablation procedure. Excimer laser ablation in the
form of photorefractive keratectomy (PRK) was performed in the
center of each cornea following epithelial debridement. A
conventional, myopic, -10 diopters (D) ablation was used over a
6 mm optical zone (OZ), with a central ablation depth of 168 mm
(Planoscan 4.14; Bausch & Lomb Inc.) for all eyes treated with
DMSO/Celluvisc, Celluvisc and all but 2 eyes treated with
Rosiglitazone. More recently, upgrading of the laser system to
Zyoptix (Bausch & Lomb Inc.) changed the stromal ablation depth
to ,135 mm for 2 of the Rosiglitazone-treated eyes and all of the
untreated eyes. PRK was performed by one of three refractive
surgeons (SM, HH, JB) under topical (Proparacaine 0.5%, Falcon)
and surgical anesthesia (Ketamine, 5 mg?kg
21, Medetomidine
Hydrochloride 0.04 mg?kg
21), using a Technolas 217 laser
(Bausch & Lomb Inc.).
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tion of the stroma, either Rosiglitazone or a vehicle solution
consisting either of 10% DMSO/Celluvisc or Celluvisc was
applied and held in place on the stromal bed using a saturated,
sterile, gelatin sponge (Surgifoam
TM; Ethicon) for 2 minutes. Each
eye then received a drop of antibiotic solution (Neomycin,
Polymyxin B Sulphate, Gramicidin Ophthalmic Solution USP,
Bausch & Lomb Inc.). For the following 2 weeks, each
Rosiglitazone-treated cat eye received 1 drop (50 ml) of 10 mM
Rosiglitazone (Cayman Chemical Company) diluted in vehicle
solution consisting of 10% DMSO in Celluvisc twice per day and
one drop of antibiotic daily. Pilot testing showed this dosage
regimen to be well tolerated and to cause no overt corneal or
ocular toxicity. Control eyes received identical amounts of either
10% DMSO/Celluvisc or Celluvisc vehicle solutions, followed by
1 drop of antibiotic daily. The Rosiglitazone vehicle contained
10% DMSO for two reasons: (1) Rosiglitazone is lipophilic and
can be well dissolved in DMSO, and (2) DMSO is known to
enhance drug penetration through membranes and tissues [62], an
important factor here as administration continued for 1 week after
epithelial closure. A separate group of cat eyes were treated with
just Celluvisc, in order to control for the possible anti-fibrotic
effects of DMSO. Data from some of these control eyes were
reported in a previous publication from our group [27]. Finally, a
set of eyes received no treatment after PRK other than daily
administration of antibiotic drops (Neomycin, Polymyxin B
Sulphate, Gramicidin Ophthalmic Solution USP, Bausch & Lomb
Inc.). This latter set of eyes served as untreated controls for the
possible biological and optical effects of Celluvisc in promoting
corneal wound healing.
In vivo confocal imaging. Confocal imaging of the central
cornea was performed in each eye before and 2, 4, 8 and 12 weeks
after laser ablation to examine changes in the appearance of cells
and of the extracellular matrix in the stroma, and to assess changes
in endothelial cell density. Cats were anesthetized as for PRK and
imaged using the Retina Tomographer with the Rostock Cornea
Module (Heidelberg Engineering, Dossenheim, Germany). Lubri-
cating gel (Genteal, Novartis) was placed on each eye and on the
contact cap. Correct alignment was attained to the central cornea,
focus was set to the epithelium and several automated volume
scans, each 58 mm in depth, were performed until the endothelium
became visible. Scans were recorded as digital video sequences
and Image J (NIH) was used to count endothelial cells within the
4006400 mm field of view. Cell density was then expressed as the
number of cells/mm
2.
Optical Coherence Tomography (OCT). A custom-built,
anterior segment OCT was used to image feline corneas before
and 2, 4, 8 and 12 weeks after laser ablation in order to measure
changes in backscatter reflectivity (an index of haze) within the
stroma, as well as changes in the thickness of the epithelial and
stromal layers [32,63,64,65,66,67,68]. Cats were anesthetized as
detailed above, lubricating gel (GenTeal, Novartis) was applied to
the ocular surface, the head was stabilized and the OCT was
centered on the pupil. Videos of the central 10 mm of each cornea
were collected at 8 frames/sec. At least ten images were extracted
at each time-point to carry out the following measurements:
For thickness measurements, custom software [68,69] was used
to obtain a normalized intensity profile across a rectangular area
105 mm wide, spanning the entire thickness of the cornea, 1 mm
nasal (to avoid the specular reflection) to the middle of each image.
The thickness of the epithelium and stroma were estimated by
measuring the difference between relevant intensity peaks in each
profile [68,69].
Backscatter reflectivity was computed from 4 sampling lines in
each of 10 corneal images/eye/timepoint. Of the 4 sampling lines,
2 were on each side of the central pixel of each image, starting
about 1 mm from the corneal center, and with each pair of lines
further separated by ,1 mm. A pixel intensity profile from
epithelium to endothelium was created for each line (Image J,
NIH) before averaging across all 4 lines. To compensate for
fluctuations in laser strength, this average profile was normalized
to the mean pixel intensity in a background region (exterior to the
cornea) in each image. The region of the curve corresponding to
the stroma was then divided into thirds to compute the average,
normalized pixel intensity over the anterior and posterior thirds of
the cornea in each image. Normalized pixel intensity values over
the anterior and posterior thirds of the cornea were then averaged
across 10 images/eye/timepoint.
In all cases, measurements collected from OCT images were
localized within the laser ablation zone in each eye.
Wavefront analysis in awake, fixating cats. Wavefront
measurements were performed pre-operatively and 2, 4, 8 and 12
weeks post-PRK with a custom-built Hartmann-Shack wavefront
sensor, in order to quantify changes in ocular wavefront
aberrations induced by both the laser ablation and pharmacolog-
ical treatments administered post-operatively. Six of the cats
(12 eyes) used in this study (2 in each of the Rosiglitazone,
DMSO/Celluvisc and Celluvisc treatment groups) were behav-
iorally trained to fixate on single spots of light presented on a
computer monitor as previously described [27,32,70]. The sensor
was aligned to the visual axis of one eye with a pupil camera, while
the other eye fixated a spot of light presented on a dark computer
monitor [27,32,70]. One hundred to two hundred video frames of
each eye’s spot array patterns were collected at each time-point.
Table 1. Number of eyes that underwent laser ablation, followed by OCT imaging, confocal imaging and/or wavefront sensing
(WFS) at each post-operative time-point.
10 mM Rosiglitazone DMSO/Celluvisc Celluvisc Untreated (no WFS)
# eyes lasered 8 12 10 8
# eyes imaged -
confocal, OCT (WFS)
2 weeks 7 (4) 12 (4) 8 (4) 6
4 weeks 6 (4) 8 (4) 6 (4) 6
8 weeks 4 (4) 4 (4) 4 (4) 4
12 weeks 4 (4) 4 (4) 4 (4) 4
Note that the number of eyes used for wavefront analysis (in brackets, where applicable) is identical to the number of eyes imaged at the 12wk post-operative
timepoint.
doi:10.1371/journal.pone.0070785.t001
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wavefront errors were calculated using a 2
nd–10
th order Zernike
polynomial expansion according to published standards for
reporting aberration data of the eye [71]. The measurements
were centered on the ablation optical zone by shifting a 6 mm
centroiding area (analysis pupil) manually to find the wavefront
that yielded the most negative defocus (j=4) value, i.e. the
maximal treatment effect [72]. For calculation of preoperative
wavefront aberrations, the analysis pupil was shifted according to
the mean post-operative offset relative to the pupil center. The
following root mean squares (RMS) were also calculated at each
time-point, ultimately being expressed in terms of magnitude
change relative to pre-operative values in order to compensate for
differences in baseline between animals: lower order RMS
(LORMS) for j=3 to 5; astigmatism RMS for j=3,5, 11, 13,
23, 25, 39, 41, 59 and 61; higher-order RMS (HORMS) for j=6
to 65; coma RMS for j=7,8,17,18,31,32,49 and 50; spherical
aberration RMS for j=12,24, 40, 60; and residual RMS for all
non-coma and non-spherical higher-order aberrations.
Immunohistochemistry. Following euthanasia, corneas
were excised and drop-fixed in 1% paraformaldehyde/0.1 M
phosphate buffered saline (PBS), pH 7.4 for 10 min. They were
then transferred to 30% sucrose/0.1 M PBS, and stored at 4uC for
2 days. After embedding into blocks (Tissue TekH O.C.T.
Compound, Sakura Finetek), serial 20 mm-thick cross-sections
were cut on a cryostat (2800 Frigocut E
TM; Leica), mounted on
microscope slides and stored in a –20uC freezer until ready to
stain.
Slides containing 3 corneal sections each were air dried and
rinsed in 0.01 M PBS. Two sections per slide were incubated
overnight at 4uC with 2 mg?mL
21 mouse monoclonal anti-aSMA
antibody (clone 1A4, Sigma Aldrich). The third section was
incubated with 0.1 M PBS as a negative control. After washing off
the primary antibody with 0.01 M PBS, sections were reacted with
anti-mouse IgG tagged with AlexaFluorH 488 (2 mg?mL
21,
Molecular Probes), followed by propidium iodide (0.1 mg?mL
21,
Invitrogen) to label cell nuclei. Double-labelled sections were
imaged using an Olympus AX70 fluorescence microscope and
photomicrographs were collected via a high resolution-video
camera interfaced with a PC running the ImagePro software
(MediaCybernetics).
In vitro Experiments
Isolation and culture of primary feline corneal
fibroblasts. Whole eyeballs were excised immediately post-
mortem from young, adult domestic short-hair cats (felis cattus) and
placed into Optisol-GS (Bausch & Lomb, Inc.). The corneal
epithelium was scraped off prior to dissection of the cornea just
inside (and excluding) the limbus, after which the endothelium was
also removed by scraping. The isolated corneal stroma was then
washed with DMEM/F12 (Cellgro
TM) with 1% Penicillin/
Streptomycin (P/S, Gibco), rinsed with sterile balanced salt
solution enriched with bicarbonate, dextrose, and glutathione
(BSS plus, Alcon), and placed into 5 mg/ml Dispase II (Roche
Diagnostics) in DMEM/F12 with 1%P/S overnight at 4
oC. The
next day, after mild shaking for 30 mins at 37u, the supernatant
was discarded and the Dispase-treated tissue was incubated in
1 mg/ml Collagenase (Clostridium histolyticum, C8176, Sigma-
Aldrich) with DMEM/F12 with 1%P/S at 37
oC for 45 min.
The digested stromal material was centrifuged at 700 rpm for
2 min to remove undigested tissue. The resulting supernatant,
containing mostly stromal fibroblasts, was centrifuged again at
1500 rpm for 5 min and the pellet resulting from this latest round
of centrifuging (presumably pure fibroblasts) was re-suspended in
2 ml of Fibroblast Growth Factor (FGF)-containing medium (C-
23010, PromoCell GmbH). The number of cells obtained was
counted and the cells were seeded onto culture plates
(Cat.#628160, Greiner Bio-One). Two eyeballs yielded approx-
imately 1610
5 primary corneal fibroblasts. The cells were grown
in FGF medium, refreshed every second day. After the second
passage, the medium was changed to DMEM/F12 with 5% horse
serum (HS - cat.#P5552, Sigma Aldrich) and refreshed every
second day until passages 6 or 7, at which point the cells were used
for the experiments below, which were performed in triplicate.
Effect of rosiglitazone on TGFb-induced expression of
aSMA and collagen I in feline corneal fibroblasts. Passage
6–7 feline, corneal fibroblasts were seeded at a density of 2.5610
4–
5.0610
4 cells/well in 6-well plates containing DMEM/F12
containing 5% HS. After attachment, which usually took 1–
1.5 hrs, the medium was changed to one containing DMEM/F12
with 1% HS for 1day in order to promote cellular quiescence.
Cells were then pre-treated with Rosiglitazone in 1% HS in
DMEM/F12 medium for 30 min. After this time elapsed, TGFb1
(1ng/ml – R&D Systems Inc.) was added to the medium and the
cells were incubated for up to 3 days (cells were prepared for
western blotting after 1, 2 or 3 days of incubation) without any
medium changes. Cells were washed twice with 1x Dulbecco’s
Phosphate Buffered Saline (DPBS, calcium/magnesium free,
Cellgro). RIPA lysis buffer (50 mM Tris-cl pH 7.4, 150 mM
NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mM sodium
orthovanadate, 1 mM PMSF, 1x complete mini protease inhibitor
cocktail ) was then added to the cells for 15 mins on ice, after
which the lysates were collected and centrifuged for 10 mins at
12,000 RPM. The pellets were discarded and the protein
concentration of residual lysates was determined using a Micro
BCA kit (Bio-Rad).
In the present experiments, western blots were used to detect
the expression of aSMA and Collagen I relative to the expression
of tubulin. An 8% gel was run using 3–5 mg of cell lysates
separated by electrophoresis, transferred to nitrocellulose mem-
brane. Primary antibodies (mouse monoclonal anti-aSMA,
1:10,000, Thermo Scientific; anti-tubulin, 1:5,000, Santa Cruz;
anti-Collagen I (LF-68), 1:5,000 gifted from Dr. Larry Fisher,
National Institute of Dental and Craniofacial Research, Bethesda,
MD) were incubated overnight at 4uC. Secondary antibodies (anti-
mouse IgG or anti-rabbit IgG-horseradish peroxidase, GE
Healthcare) were then applied for 1 hr at room temperature.
Bands were detected by Western Lightning
TM plus-ECL (from
PerkinElmer). Finally, the membranes were scanned with a chemi-
doc machine (Bio-Rad) and the resulting images were imported
into Image J (NIH) for measurement of relative expression levels.
For the background intensity levels, we measured two areas (one
above and one below each reactive band), and averaged them
together. This background level was then subtracted from the
average pixel intensity over the reactive band. The band’s net
intensity value was then divided by the average net intensity value
of its corresponding loading control (reacted for tubulin), and the
result was further normalized to that attained following stimulation
with TGFb alone.
Statistical Analysis
When three or more intervention groups were compared, inter-
group differences in reflectivity, corneal thickness, wavefront
aberrations and protein expression were compared with a repeated
measures ANOVA (for repeated measures over time) or a two-way
ANOVA, or a one-way ANOVA for western blot analyses. When
only two groups were compared, a two-sided Student’s t-test was
performed. A probability of error of P,0.05 was considered
Rosiglitazone in Corneal Wound Healing
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e70785statistically significant. All ANOVAs were performed using the
SPSS 20.0.0 software package (SPSS Inc.), while t-tests were
performed in Excel (Microsoft Office).
Results
Topical Rosiglitazone Inhibits aSMA Induction after
Excimer Laser Ablation of the Cornea
Cat eyes in this study healed quickly, with epithelial regrowth
over the denuded stromal surface complete between the 3
rd and
5
th days post-operatively. Normal, un-operated cat corneas
exhibited a complete absence of aSMA staining within the stroma
(Fig. 1A). In contrast, 2 and 4 weeks post-operatively, the ablation
zone in all lasered eyes could be identified by a thickened,
overlying epithelium (Fig. 1). However, there were clear
differences in aSMA immunoreactivity between untreated, vehi-
cle-treated (DMSO/Celluvisc and Celluvisc) and Rosiglitazone-
treated eyes. Both untreated and vehicle-treated eyes exhibited a
strong, continuous band of aSMA expression below the epithelium
(Figs. 1B, C, D), which was thicker in untreated eyes at 2 weeks
post-PRK (Fig. 1B), and essentially identical in all control groups
at 4 weeks post-PRK (Figs. 1F, G, H). In eyes treated with
10 mM Rosiglitazone, only small, thin patches of aSMA were
visible under the epithelium, alternating with aSMA-negative
zones (Fig. 1E, I). Generally, aSMA expression was strongest at 2
weeks post-PRK, decreasing at 4 weeks (Fig. 1) and disappearing
completely by 8 and 12 weeks after PRK, as previously reported
for cat eyes undergoing this exact PRK treatment [27]. At 2 weeks
post-PRK, Celluvisc and DMSO/Celluvisc treatments significant-
ly reduced aSMA staining relative to the untreated corneas
(contrast Figs. 1B with 1C, D). This is consistent with the
previously reported anti-inflammatory actions of both Celluvisc
and DMSO [73,74,75]. However, by 4 weeks post-PRK, any
qualitative differences between the thickness or intensity of the
aSMA bands in untreated versus vehicle-treated controls had
disappeared (contrast Figs. 1F with 1G, H). At both time-points,
there was markedly less aSMA-positive staining in Rosiglitazone-
treated eyes than in untreated or vehicle-treated corneas. Thus, by
4 weeks post-PRK, neither DMSO, nor Celluvisc appeared to
significantly influence aSMA expression – only Rosiglitazone did.
Topical Rosiglitazone Decreases Corneal Haze after Laser
Ablation
Pre-operatively, in vivo confocal imaging (Fig. 2A, B) and OCT
imaging (Fig. 2G) showed the corneal stroma to have relatively
low reflectivity. Two and 4 weeks post-operatively, both imaging
modalities showed dramatically increased reflectivity in the
ablation zone stroma (see Figs. 2C, D for confocal images;
Fig. 2H for OCT images), which decreased back towards normal
levels by 12 weeks post-operatively (Fig. 2E, F for confocal;
Fig. 2I for OCT). However, there were significant differences
between eyes treated with Rosiglitazone and those that were
exposed to vehicle solutions:
Two and 4 weeks post-operatively, OCT backscatter reflectivity
in the anterior 30% of the stroma of DMSO/Celluvisc-treated
eyes had increased by 5266.2% (mean6SEM) relative to pre-
operative levels, decreasing thereafter, until 12 weeks post-
operatively, when it was only 1062.3% greater than pre-operative
levels (Fig. 2J). A very similar pattern of results was obtained for
cat eyes treated with Celluvisc and for untreated cat eyes.
Rosiglitazone-treated eyes exhibited only a small (1567.4%)
increase in backscatter reflectivity in the anterior stroma relative
to that seen in vehicle-treated and untreated eyes at the 2 and 4
weeks post-operative time-points (black symbols in Fig. 2J). A two-
way ANOVA was conducted to examine the effect of post-
operative treatment (Rosiglitazone or DMSO/Celluvisc vehicle)
and time (2, 4, 8 and 12 weeks) on backscatter reflectivity in the
anterior 30% of the stroma. There were significant main effects of
treatment (F(1,41)=26.12, p,0.0005) and time (F(3,41)=11.349,
p,0.0005) on reflectivity, but no significant interaction between
the two (F(3, 41)=0.609, p=0.613). A similar, two-way ANOVA
was conducted to assess whether there were significant differences
between the 3 types of controls (DMSO/Celluvisc, Celluvisc and
untreated eyes) over time (2, 4, 8 and 12 weeks) in terms of
reflectivity of the anterior 30% of the stroma. We found no
significant main effect of control type (F(2,50)=0.015, p=0.985)
and no significant interaction between control type and time
(F(6,50)=1.069, p=0.394). The only significant main effect was
for time (F(3,50)=13.993, p,0.0005), with reflectivity decreasing
significantly between 2 and 12 weeks post-operatively in all 3
control groups.
As illustrated in Figure 2K, when combining all operated
corneas at 2 weeks post-PRK, backscatter reflectivity of the
posterior 30% of the stroma was greater than pre-operatively
(p=0.002, Student’s t-test). A two-way ANOVA was also
conducted to examine the effect of post-operative treatment
(Rosiglitazone versus DMSO/Celluvisc vehicle) and time (2, 4, 8
and 12 weeks) on backscatter reflectivity in the posterior 30% of
the stroma. There were significant main effects of treatment
(F(1,40)=4.702, p=0.036) and time (F(3,40)=4.518, p,0.008) on
reflectivity, but no significant interaction between the two (F(3,
40)=0.568, p=0.639). Post-hoc, Bonferroni-corrected t-tests
between these two treatment groups at individual time-points
revealed that the main significant difference in reflectivity between
Rosiglitazone and DMSO/Celluvisc treated eyes occurred at 2
weeks post-PRK (p=0.035). The reflectivity of the posterior
stroma remained higher than baseline at all time-points for
Celluvisc treated eyes, and until 12 weeks post-PRK, when it
returned to basal levels in DMSO/Celluvisc-treated eyes (Fig. 2I).
In contrast, untreated eyes exhibited a return to baseline as early
as 4 weeks post-operatively (Fig. 2I).
Rosiglitazone does not Impede Epithelial and Stromal Re-
thickening after Injury
Pre-operatively, the central stroma was 460–600 mm thick, and
the central epithelium 43–77 mm thick with no significant inter-
group differences between eyes destined for the control versus
treatment (Rosiglitazone) groups post-laser ablation (p=0.9022,
Student’s t-test).
The injury model used in the present study removed the entire
epithelial thickness and an average 16162.3 mm of stroma in the
central cornea across all eyes, as verified intra-operatively with a
Corneo-Gage Plus 2 ultrasonic pachymeter (Sonogage Inc.). Two
weeks later (at the end of pharmacological treatment), OCT
measurements showed that the epithelium had regenerated and
was in fact thicker than pre-operatively by an average of 30 mmi n
vehicle and Rosiglitazone-treated eyes, but not in untreated eyes
(Fig. 3A). A two-way ANOVA was conducted to examine the
effect of post-operative treatment (Rosiglitazone, DMSO/Cellu-
visc vehicle, Celluvisc vehicle and no treatment) and time (0, 2, 4,
8 and 12 weeks) on epithelial thickness. There were significant
main effects of treatment (F(3,117)=9.130, p,0.0005) and time
(F(4,117)=5.736, p,0.0005), as well as a significant interaction
between the two (F(12, 117)=2.815, p,0.0005). Bonferroni-
corrected post-hoc t-tests showed the untreated group to behave
significantly differently from all other groups in terms of epithelial
thickness. When comparing the 2 week epithelial thickness of each
individual group with their pre-operative values, both Rosiglita-
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than pre-operatively (p=0.04 for Rosiglitazone, p=0.01 for
Celluvisc, p=0.003 for DMSO/Celluvisc-treated eyes - Fig. 3A).
However, untreated control eyes exhibited delayed epithelial
regeneration, only catching up to the treated eyes (whether
Rosiglitazone or vehicle) by the 8
th post-operative week (Fig. 3A).
At 2 weeks post-PRK, untreated corneas exhibited significantly
thinner epithelia than pre-operatively (p=0.009, Student’s t-test).
It took until the 4
th post-operative week for untreated epithelia to
return to pre-operative central thickness values (p=0.2887,
Student’s t-test).
Central stromal thickness also increased after the ablation,
though it remained thinner than pre-operatively in all groups 12
weeks post-operatively (Fig. 3B). A two-way ANOVA was used to
examine the effect of post-operative treatment (Rosiglitazone,
DMSO/Celluvisc vehicle, Celluvisc vehicle and no treatment) and
time (0, 2, 4, 8 and 12 weeks) on stromal thickness. There was no
significant main effect of treatment (F(3,117)=2.441, p=0.068) -
only of time (F(4,117)=4.155, p=0.003), and a marginally
significant interaction between the two (F(12, 117)=1.870,
p=0.045). There appeared to be delayed stromal thickening in
the Celluvisc-treated eyes relative to the others at 2 weeks post-
PRK. However, this difference disappeared at later time-points.
By the 12th post-operative week, there were no longer any
significant differences in stromal thickness between treatment
groups. However, p,0.05 relative to pre-operative levels in each
group (p=0.027 for Rosiglitazone, p=0.0002 for DMSO/Cellu-
visc, p=0.007 for Celluvisc and p=0.027 for untreated eyes,
Student’s t-tests). Central epithelial and stromal thicknesses
remained relatively stable from 4 to 12 weeks post-laser ablation,
with no significant inter-group differences.
Whether the observed stromal thickness change reflected
regeneration or swelling is a matter of contention. At the latest
post-operative time-points, however, the hypothesis that it may
have represented regeneration was supported by 3 observations:
(1) OCT data (Fig. 2) showing that corneal haze was minimal (in
control eyes) or absent (in Rosiglitazone-treated eyes) at 12 weeks
post-op; (2) the epithelial layer was thick and well organized; and
(3) the central endothelium was normal in appearance and density
(Fig. 3C). The mean6SEM pre-operative endothelial cell density
was 2120686 cells/mm
2 and 21406150 cells/mm
2 for eyes
destined for vehicle and Rosiglitazone treatments, respectively.
Eight to 12 weeks post-laser ablation, central endothelial density
was 17886213 cells/mm
2 in DMSO/Celluvisc-treated eyes and
1912697 cells/mm
2 in Rosiglitazone-treated eyes. Neither num-
ber was significantly different from pre-operative levels
(p=0.1253 for DMSO/Celluvisc and p=0.3711 for Rosiglita-
zone, Student’s t-tests) or from each other (p=0.5814, Student’s t-
test).
Figure 1. Immuno-staining for aSMA (green) in cat corneal sections counterstained with propidium iodide (PI - red). A. Unoperated
cat cornea showing complete lack of aSMA staining. B. Cat cornea 2 weeks post-PRK, which received no treatment. Note the very thick band of aSMA
staining just below a thin, incompletely regenerated epithelium. C. Cat cornea treated with Celluvisc for 2 weeks after PRK and sampled 2 weeks
post-PRK. The band of aSMA staining is thinner than in B, but remains continuous and several cells thick. The epithelium is thicker than in the
untreated cornea and more cell-dense. D. Cat cornea treated with DMSO/Celluvisc vehicle solution post-operatively, sampled at 2 weeks post-laser
ablation. Note the maintained, distinct band of strong, continuous aSMA staining in the anterior stroma, just below the thick epithelium. E.
Corresponding view of the ablation zone in a cornea treated with 10 mM Rosiglitazone for 2 weeks and sampled 2 weeks post-laser ablation. There is
much less aSMA staining in the ablation zone – thin, faint bands are visible, separated by zones devoid of aSMA staining, but not of PI-positive nuclei.
This suggests that stromal cells are present, at what seems to be a fairly normal density, but that they are not myofibroblasts. The epithelium is also
fully regenerated and well-organized. F. Untreated cat cornea 4 weeks post-laser ablation showing a much thinner, but still continuous band of aSMA
staining below the ablation zone epithelium, which is now slightly thicker than at 2 weeks post-op, but still not quite normally organized. G. Cat
cornea treated with Celluvisc vehicle solution, sampled at 4 weeks post-laser ablation. Note the distinct band of strong, continuous aSMA staining in
the anterior stroma. The epithelium in this section was accidentally torn off and thus appears thinner than it actually was. H. Central ablation zone of
a cat cornea treated with DMSO/Celluvisc vehicle solution for 2 weeks and sampled 4 weeks post-laser ablation. Again, there is strong, continuous
aSMA staining in the anterior stroma, just below the epithelium, which is remarkably thickened relative to the unoperated condition (and normal
corneas). I. Cat cornea treated with 10 mM Rosiglitazone in DMSO/Celluvisc for 2 weeks after PRK, and sampled at 4 weeks post-laser ablation. Just as
in the 2 weeks condition for this treatment group, there was very little aSMA staining, organized into thin, faint clusters of aSMA positive cells
separated by zones devoid of aSMA staining, but not of PI-positive nuclei. The epithelium is thick and well-organized.
doi:10.1371/journal.pone.0070785.g001
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PLOS ONE | www.plosone.org 6 August 2013 | Volume 8 | Issue 8 | e70785Figure 2. Optical imaging and the impact of Rosiglitazone treatment on wound healing in the cat cornea. Illustrative confocal images
were taken 15 mm below the basal epithelial layer of the central cornea in one eye treated with DMSO/Celluvisc vehicle solution (A, C, E), and one
eye treated with 10 mM Rosiglitazone (B, D, F) daily for 2 weeks after laser ablation. Pre-operative images (A, B) show a quiescent stroma that
appears quite similar across the two eyes. Two weeks after laser ablation, just after the end of topical treatments, both corneas showed increased
reflectivity, which was highest in the vehicle-treated eye (C) and least in the Rosiglitazone-treated eye (D). By 12 weeks post-operatively, the
Rosiglitazone-treated eye’s reflectivity was back down to basal levels (F), while the vehicle-treated eye remained hazier than pre-operatively (E). OCT
images of a Rosiglitazone-treated eye collected pre-operatively (G), 4 weeks (H) and 12 weeks (I) post-operatively illustrate a bright zone of
reflectivity at 4 weeks post-op, which was not present pre-operatively and is lost by 12 weeks post-op. J. Plot of normalized intensity change in the
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Higher Order Aberration Induction
Pre-operatively, cat eyes were slightly myopic, hovering around
1 mm of positive defocus over a 6 mm pupil (corresponding to
about 20.9 D), with low astigmatism (Fig. 4B). Higher order
aberrations (HOAs) were very small, with vertical coma (j=7)
being the most significant (Fig. 4C). There were no significant
differences in lower- or higher-order aberrations between cat eyes
destined for vehicle versus Rosiglitazone treatment.
Post-operatively, the situation changed radically. By 12 weeks
after surgery, after wound healing was complete and the corneas
appeared to have stabilized biologically, significant differences
were seen between vehicle-treated eyes (whether with DMSO/
Celluvisc or Celluvisc – there were no significant differences
between these two groups) and those that received Rosiglitazone
post-laser ablation. While all eyes became more hyperopic, eyes
that received vehicle solutions ended up with 25.260.4 mm and
26.260.4 mm of defocus over a 6 mm-diameter optical zone for
anterior 30% of the stroma relative to pre-operative values (dotted line at zero), measured from OCT images such as those in G–I. K. Similar plot of
normalized pixel intensity change against post-operative time for the posterior 30% of the stroma in either untreated, vehicle-treated or
Rosiglitazone-treated cat corneas post-excimer laser ablation. Error bars=SEM. N=number of eyes, which differs at different time-points (see Table 1).
DMSO/Cell=DMSO/Celluvisc treated eyes. Cell=Celluvisc treated eyes.
doi:10.1371/journal.pone.0070785.g002
Figure 3. Effect of post-operative treatments on stromal and epithelial thickness. A. Plot of change in central epithelial thickness in the 4
experimental groups showing the average amount of epithelial thickness scraped off prior to laser ablation (time-point 0) and the hyperplasia in this
layer that was already evident 2 weeks later in all but the untreated eyes, remaining relatively stable thereafter. By 8 weeks post-PRK, there is no
longer a significant difference between experimental groups. B. Plot of change in central stromal thickness averaged across eyes in the 4
experimental groups, showing the amount of stromal thickness removed by laser ablation (at time-point 0) and the significant stromal thickening
observed as soon as 2 weeks later in all groups (albeit to different extents). No significant differences were noted between groups after 4 weeks post-
PRK. Error bars=SEM. N=number of eyes, which differs at different time-points (see Table 1). DMSO/Cell=DMSO/Celluvisc treated eyes.
Cell=Celluvisc treated eyes. C. In vivo confocal imaging of the endothelial layer pre-operatively and 2 weeks post-laser ablation (at the end of topical
treatment) in one DMSO/Celluvisc-treated cat eye and one eye that had received 10 mM Rosiglitazone post-operatively. Note tightly packed, mostly
hexagonal cells, with no gaps between them, which are evident in both treatment groups.
doi:10.1371/journal.pone.0070785.g003
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PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e70785Figure 4. Impact of laser ablation and Rosiglitazone treatment on the magnitude of ocular wavefront aberrations. A. Picture of a
DMSO/Celluvisc-treated cat eye 2 weeks after surgery, illustrating ocular appearance and the quality of the spot array patterns imaged with the
wavefront sensor at this time-point. Note the haziness of spots at this time-point, as well as the distortion clearly visible at the edge of the laser
ablation on the cornea and the spot array pattern. The dashed white circle denotes the 6 mm diameter optical zone over which wavefront
aberrations in the graphs below (B–E) were quantified. B. Plots of mean pre-operative 2
nd order aberrations (j=3–5) in the 3 treatment groups
(Rosiglitazone-treated, DMSO/Celluvisc and Celluvisc), indicating near emmetropia in all cases. C. Pre-operative magnitude of higher order
aberrations (HOAs) up to the 5
th order (J=6–20), showing no significant inter-group differences and relatively low HOAs over a 6 mm pupil. Note
however, that primary coma (j=7) and spherical aberration (j=12) were the dominant HOAs in all groups. D. Mean lower order aberrations over a
6 mm pupil 12 weeks post-PRK showing virtually no change in astigmatism terms (j=3 and 5) but a substantial myopic shift in the defocus term
(j=4), which was significantly greater for vehicle-treated eyes than in those treated with Rosiglitazone post-operatively. E. Plot of mean HOAs 12
weeks post-PRK showing a progression towards more negative primary coma terms (j=7 and 8) for Rosiglitazone-treated eyes, while primary coma
terms in vehicle-treated eyes were more positive, on average. Spherical aberration (j=12) became more positive in all groups, by about the same
amount. Error bars=SEM, N=number of eyes, * p,0.05, Student’s t-test for differences relative to Rosiglitazone-treated eyes.
doi:10.1371/journal.pone.0070785.g004
Rosiglitazone in Corneal Wound Healing
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e70785DMSO/Celluvisc and Celluvisc-treated eyes respectively (white
and grey bars in Fig. 4D), which represents about a 5–6D change
relative to pre-operative values. In contrast, eyes treated with
Rosiglitazone had only 22.560.3 mm of defocus over a 6 mm
diameter zone (black bars in Fig. 4D), a change of only 2.8D
relative to pre-operative values. As expected given the Planoscan
ablations used, astigmatism terms remained unchanged (close to
zero) in both groups (Fig. 4B). Thus, at the end of the 12 week
post-surgical observation period used in this experiment, Rosigli-
tazone-treated eyes were closer to emmetropia by a factor of 2
relative to vehicle-treated eyes. A two-way repeated measures
ANOVA with treatment group as the between-subject factor and
time as the within-subject factor revealed a significant main effect
of time (F(2,10)=15.621, p=0.001) and a significant interaction
between treatment group and time (F(2,10)=5.804, p=0.021). By
12 weeks post-laser ablation, LORMS change was significantly
greater in DMSO/Celluvisc-treated than in Rosiglitazone-treated
eyes (p=0.0008, Student’s t-test). In contrast, astigmatism RMS
did not change from pre-operative values for any of the treatment
groups, at any of the time-points examined.
A cursory comparison between plots in Figs. 4C and E shows
that some higher order aberrations were clearly altered in both
vehicle- and Rosiglitazone-treated eyes. The results of RMS
analysis, used to tease out some of the more subtle differences in
HOA changes, are as follows: prior to laser ablation, HORMS in
eyes destined for Rosiglitazone treatment was around
0.4260.03 mm. Residual (non-coma, non-spherical) HOAs ac-
counted for most (4965%) of the HO variance, followed by coma-
like aberrations (3967%), then spherical-like aberrations
(1064%). There were no statistically significant differences in
any of the terms examined between the 3 groups. Post-operatively,
some HOAs (Fig. 4E) and HORMS (Fig. 5A) increased in both
Rosiglitazone and vehicle-treated eyes. However, the nature of,
the temporal pattern of induction, and the persistence of these
aberrations differed significantly between Rosiglitazone and
vehicle-treated eyes. In particular, there were two interesting
observations: first, there was a general delay in HOA induction in
Rosiglitazone-treated eyes versus those receiving vehicle after the
laser ablation, with increases in HORMS, coma RMS and
residual RMS first significant at 2 weeks for DMSO/Celluvisc and
Celluvisc-treated eyes, and at 4 weeks for Rosiglitazone-treated
eyes. The second interesting observation was that by the 12
th post-
operative week, in Rosiglitazone-treated eyes all HOAs had
decreased back to levels not significantly different from pre-
operative values, except for spherical aberration RMS, which
remained significantly elevated relative to pre-operative values
(Fig. 5D). In vehicle-treated eyes, all HOAs remained elevated,
except for coma RMS, which decreased back to normal (Fig. 5).
As an illustration, by 12 weeks post-laser ablation, residual HOAs
only accounted for 1566% of the HO variance in Rosiglitazone-
treated eyes, a significant decrease even relative to pre-operative
levels (p=0.019, Student’s t-test – Fig. 5B). In DMSO/Celluvisc
and Celluvisc vehicle-treated eyes, these irregular, fine-grained
HOAs still accounted for 35613% and 4663% of the HO
variance at 12 weeks, respectively (Fig. 5B). In contrast, no
statistically significant differences in the magnitude of induced SA
were observed between the treatment groups at 12 weeks
(Fig. 5D). This was verified with a two-way ANOVA that probed
the effects of post-operative treatment (Rosiglitazone, DMSO/
Celluvisc vehicle or Celluvisc vehicle) and time (2 and 12 weeks) on
SA RMS change. There was no significant main effect of
treatment (F(2,18)=3.289, p=0.061) or time (F(1,18)=1.129,
p=0.302), and there was no significant interaction between the
two (F2, 18)=2.053, p=0.157).
In summary, vehicle-treated eyes tended to show a rapid
induction of the main HOAs following PRK, and all but coma-like
aberrations were maintained long-term (i.e., to 12 weeks post-
PRK). The only apparent contribution of DMSO to the effect of
these vehicle solutions was to delay the increase in spherical-like
HOAs until 4 weeks post-PRK (Fig. 5D). Rosiglitazone-treated
eyes experienced a delayed induction of all main classes of HOAs,
and out of these, only spherical-like HOAs persisted out to 12
weeks post-PRK.
Rosiglitazone Blocks TGFb-induced aSMA Expression in
Cultured Feline Corneal Fibroblasts
Our in vivo results suggested that topical application of
Rosiglitazone to the injured cat cornea inhibited myofibroblast
differentiation. To verify whether Rosiglitazone exerted this effect
directly on stromal fibroblasts, primary feline corneal fibroblasts
were cultured and pre-treated with different doses of Rosiglitazone
before being stimulated by the addition of TGFb. Western blotting
performed on a sample of the cells after 1, 2 and 3 days in culture
revealed that in the absence of TGFb stimulation, basal levels of
aSMA expression were close to zero even after 3 days in culture
(Figs. 6A, B). It then took 3 days for aSMA expression to peak
after TGFb stimulation, but the strongest dose of Rosiglitazone
that could be used without inducing toxicity (75 mM) decreased
aSMA expression after 2 and 3 days in culture (Fig. 6A,B). After
3 days in culture, treatment with 75 mM Rosiglitazone reduced
aSMA expression relative to levels induced by 1 ng/ml TGFb by
between 79 and 98% (mean6SD=9068%). A two-way ANOVA
that probed the effects of treatment (control, 1 ng/ml TGFb or
75 mM Rosiglitazone) and time (1, 2 and 3 days in culture) on
aSMA expression showed a significant main effect of treatment
(F(2,18)=34.226, p,0.0005), time (F(2,18)=19.098, p,0.0005),
and there was also a significant interaction between the two (F4,
18)=16.600, p,0.0005). Post-hoc Bonferroni corrected t-tests
showed that significant effects between treatments across time
resided only in the TGFb-treated cells. There were no significant
differences in aSMA expression between control and 75 mM
Rosiglitazone treatment groups across time.
Discussion
According to the World Health Organization, corneal scarring
is the second major cause of blindness worldwide behind cataracts
[76]. Over the last 25 years, significant progress has been made in
understanding the cellular and molecular bases of corneal fibrosis,
the precursor to scarring. However, we cannot yet effectively
control fibrosis in the cornea or elsewhere in the body. Here, we
show that topical administration of Rosiglitazone to the eye can
effectively block myofibroblast differentiation, a hallmark of
corneal fibrosis, while allowing the epithelium and stroma to
return to a normal thickness, restoring corneal shape, structure
and optical quality to near-normal levels. Cell culture experiments
confirmed the anti-fibrotic effects of Rosiglitazone on isolated
corneal fibroblasts and revealed a significant impact of Rosiglita-
zone on aSMA expression.
Rosiglitazone Blocks TGFb-induced Expression of aSMA
in the Cornea in vivo and in vitro
Excimer laser ablation of the kind performed here (i.e. PRK for
high myopia) is known to generate a strongly-stained band of
aSMA expression in the sub-epithelial stroma of a range of species,
including humans, rabbits and cats [27,32,60,77,78,79]. General-
ly, this band becomes visible 1 week post-PRK, increasing in
intensity by 2 weeks post-PRK, and decreasing thereafter until it
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was confirmed in vehicle-treated and untreated eyes in the present
study. Interestingly, in spite of DMSO being a known anti-
inflammatory agent [73] and the carboxymethylcellulose in
Celluvisc actively promoting epithelial wound healing in the
cornea [74,75], these two vehicle solutions only dampened, rather
than eliminated aSMA expression relative to untreated eyes. Only
the presence of Rosiglitazone effectively blocked stromal aSMA
expression, with only a few, interspersed patches of myofibroblasts
observed 2 and 4 weeks post-PRK and no detectable staining at 8
and 12 weeks. Just as with anti-TGFb treatment in two prior
studies [27,80], aSMA expression did not suddenly increase after
daily anti-fibrotic treatment was discontinued, suggesting that
early inhibition of myofibroblast differentiation may be sufficient
for long-term fibrosis control after excimer laser ablation of the
stromal surface. An important question that remains to be
answered is whether starting application of Rosiglitazone at later
time-points post-injury is able to prevent or reverse the scarring
process. Finally, consistent with the effectiveness of Rosiglitazone
at blocking aSMA expression in vivo, this PPARc ligand also
reduced aSMA expression in cultured, feline, corneal fibroblasts
stimulated with TGFb.
Topical Rosiglitazone Decreases post-operative Haze in
the Anterior Corneal Stroma
In Rosiglitazone-treated cat eyes, low aSMA expression was
accompanied by a significantly decrease in laser-induced haze in
the anterior stroma, as measured by OCT backscatter reflectivity
and confirmed qualitatively with confocal imaging. By 8 and 12
weeks post-PRK, anterior stromal reflectivity in Rosiglitazone-
treated corneas was indistinguishable from pre-operative levels,
and significantly lower than in vehicle-treated and untreated
corneas. It is possible that low levels of light scatter were caused by
a reduction in cellular repopulation of the injured tissue (due to
Figure 5. Change in higher order wavefront aberration root mean square (RMS) 2 and 12 weeks after laser ablation relative to pre-
operative levels. A. Plot of change in higher order RMS (HORMS) at 2 and 12 weeks post-laser ablation in Rosiglitazone-, DMSO/Celluvisc and
Celluvisc -treated cat eyes. HORMS increased significantly relative to pre-operative levels in all groups of eyes, and this elevation was maintained all
the way out to 12 weeks post-PRK, but there were no significant inter-group differences in the magnitude of the change, whose significance was
likely driven predominantly by spherical aberration (SA). B. Plot of change in residual HORMS illustrating significantly smaller increases in
Rosiglitazone-treated eyes relative to both vehicle-treated eyes. These differences are maintained out to 12 weeks post-operatively. C. In contrast, the
magnitude of increase in coma RMS is not significantly different between treatment groups, at either 2 or 12 weeks post-PRK. D. Finally, spherical
aberration (SA) RMS does not appear significantly increased 2 weeks post-laser ablation in Rosiglitazone or DMSO/Celluvisc-treated eyes, but all 3
groups show a similar, positive change in SA RMS relative to pre-operative values by 12 weeks post-PRK. Error bars=SEM, N=number of eyes, *
p,0.05, Student’s t-test.
doi:10.1371/journal.pone.0070785.g005
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inspection of histological sections stained with propidium iodide (a
nuclear stain) did not indicate that this was occurring in our
samples, cell counts and further analysis would be required to
completely rule this out. However, assuming that decreased cell
density does not account for the lack of haze observed presently,
the remarkable implication here is that by 2 months post-laser
ablation, from an optical clarity stand-point, Rosiglitazone-treated
corneas looked macroscopically like they had never been operated
upon. Importantly, post-operative treatment with just DMSO
and/or Celluvisc did not significantly improve corneal haze
relative to untreated corneas post-PRK.
Rosiglitazone Treatment does not Block Corneal
Thickening after Laser Ablation
Perhaps one of the most striking observations in the present
study was the speed with which the epithelial and stromal
thicknesses increased following the laser ablations in all treatment
groups. Significant thickening of the epithelium above pre-
operative levels occurred in Rosiglitazone and vehicle-treated eyes
by 2 weeks, and in untreated eyes by 8 weeks post-operatively. The
delayed epithelial thickening in untreated eyes is consistent with
the fact that these were the only eyes not receiving Celluvisc-
containing eye drops post-PRK. As mentioned earlier, Celluvisc is
known to promote epithelial healing in the cornea [74,75].
Regardless, by 12 weeks post-operatively, all eyes in the present
study exhibited central epithelium that was about 30 mm thicker
on average than pre-operatively. This was a very different
outcome than obtained previously with anti-TGFb treatment
post-PRK in the cat [27], and also in rabbits [81,82] where
epithelial thickness eventually returned to normal rather than
exhibiting hyperplasia. A possible explanation for this difference is
that the prior studies used much shorter treatment periods than in
the present experiments. The other possible explanation is that
neutralizing antibodies to TGFb are known to inhibit epithelial
regrowth in corneal organ culture and in epithelial wound healing
studies in mice [83,84]. It is thus conceivable that even when anti-
TGFb antibodies were mixed with Celluvisc in prior studies
[27,80], the epithelial growth-promoting effects of Celluvisc were
likely insufficient to completely counteract the inhibition enacted
by anti-TGFb antibodies on epithelial cells. In the present
experiments, Rosiglitazone was administered with both DMSO
and Celluvisc. In addition to the epithelial-growth promoting
effects of Celluvisc, DMSO is an effective anti-ulceration agent in
skin [85,86] and could play a similar role in the cornea.
Ultimately, when Rosiglitazone was dissolved in DMSO/Cellu-
visc, the compound solution did not inhibit re-epithelialization.
Whether this was because Rosiglitazone did not inhibit the SMAD
pathway in TGFb signaling, and/or because Rosiglitazone
allowed phosphorylation of p38-MAPK and its translocation to
the nucleus, which appears to be necessary for epithelial
Figure 6. Anti-fibrotic effects of Rosiglitazone on cultured feline corneal fibroblast. A. Representative western blots showing protein
levels for aSMA. Tubulin levels were assayed as a loading control. For this experiment, cells were pretreated with 25 mM, 50 mM, and 75 mM
Rosiglitazone for 30 min, before adding 1 ng/ml of TGFb in DMEM/F12 containing 1% HS. The cells were cultured in this treated medium for 1, 2 or
3 days and then harvested for western blotting. While some effect could be observed at lower doses, Rosiglitazone clearly inhibited aSMA expression
at 75 mM, while tubulin levels remained stable. B. Plots of relative expression of aSMA normalized to densitometric values obtained in cells stimulated
with 1 ng/ml TGFb for each culture day sampled. Data shown are means6SD, averaged over 3 experiments, and they confirm a statistically significant
inhibitory effect of Rosiglitazone on aSMA. * P,0.05, Student’s t-test relative to TGFb-only condition.
doi:10.1371/journal.pone.0070785.g006
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epithelial re-growth is highly desirable for corneal wound healing.
An open epithelium represents an irritation to the corneal surface
that prolongs secretion of TGFb, which in turn, exacerbates the
intensity of the fibrotic response in stromal keratocytes [87,88].
Clearly, this was avoided in corneas treated with Rosiglitazone/
DMSO/Celluvisc post-PRK.
The central stroma of vehicle-treated, Rosiglitazone-treated and
untreated cat eyes also thickened significantly by 2 weeks post-laser
ablation. In contrast, the stroma of eyes receiving anti-TGFb
treatment for 2 weeks post-PRK remained ,160 mm thinner than
normal, even as long as 3 months post-operatively [27]. Significant
stromal regeneration was previously observed in rabbit models of
PRK [80,81,82], although in that species, it appeared to take a
long time (closer to 6 months). Of note, however, is the fact that
short-term anti-TGFb treatment in the rabbit did not inhibit
stromal regeneration [80]. Together with the present Rosiglita-
zone effects, this may suggest that aspects of stromal regeneration
could be regulated via TGFb-independent pathways.
In addition, the possibility that the post-operative increase in
corneal thickness observed in our in vivo experiments was due to
swelling remains, especially at early time-points post-PRK.
Increased water infiltration into the stroma, resulting in swelling,
could occur in two main ways – a leaky endothelium and a leaky
epithelium. However, confocal imaging revealed an endothelium
that looked normal and unstressed at all time-points, with no
polymegathism or cell vacuolization. Though limited to sampling
of the central cornea, analysis of in vivo confocal images showed no
significant changes in endothelial cell density across post-operative
time-points. Thus, swelling as a result of endothelial failure was
unlikely. At later time-points, the epithelium was thick (in fact,
thicker than normal – see Fig. 1), well stratified and unlikely to
have been leaky, although this was not explicitly tested in the
present study. Nevertheless, corneal swelling is normally accom-
panied by haze, yet by 8 and 12 weeks post-laser ablation, the
OCT-based stromal reflectivity measures in Rosiglitazone-treated
eyes indicated no haze in either the anterior or posterior thirds of
the cornea. Thus, while we cannot rule out that the vehicle-treated
and untreated corneas remained somewhat edematous throughout
the experimental period, at least the Rosiglitazone-treated eyes did
not appear to suffer from this problem.
Rosiglitazone Restores Near-emmetropia Following Laser
Ablation of the Cornea
Given that the cornea’s total thickness returned to within 20 mm
of normal within 2 weeks after complete epithelial removal and
laser ablation of the central stroma to a depth of ,160 mm, we
predicted that this would erase the wavefront aberration changes
induced by the surgery. However, this only happened in
Rosiglitazone-treated eyes. Vehicle-treated eyes exhibited about
5–6D of hyperopic shift and a significant, lasting increase in
HOAs, including spherical aberration (SA) and residual HOAs – a
result consistent with our previous data using -10D PRK over a
6 mm optical zone in cats [27]. Rosiglitazone-treated eyes
exhibited less than half this defocus shift, going from 1D of
myopia to 1D of hyperopia. Thus, in Rosiglitazone-treated eyes,
the ablation shape was largely erased. Since myofibroblast
differentiation was blocked only in Rosiglitazone-treated eyes
(and not in any of the vehicle-treated eyes), we may conclude that
blocking myofibroblast differentiation and the tissue contraction
these cells would enable, together with a return to near-normal
total corneal thickness worked together to bring corneal optics in
Rosiglitazone-treated eyes back towards emmetropia. In addition,
Rosiglitazone-treated eyes exhibited delayed induction of HOAs
(by 2 weeks) relative to vehicle-treated eyes, and overall, they
exhibited lower residual (non-coma, non-spherical) HOAs 12
weeks post-operatively. However, once induction of spherical-like
HOAs was observed at 4 weeks post-PRK, it persisted until the
end of the observation period, at 12 weeks post-PRK. Generally,
our results with Rosiglitazone treatment appear consistent with
our prior observations following anti-TGFb treatment post-PRK
in the same cat model, in which we showed decreased
myofibroblast differentiation to be correlated with reduced
residual HOA induction [27]. Another similarity between
Rosiglitazone and anti-TGFb treatment was that both ultimately
resulted in a persistent increase in spherical aberration. However,
with respect to HOAs, Rosiglitazone did exhibit a distinct
advantage over anti-TGFb treatment: in the latter, all reductions
in HOAs observed were short-lived, being significant only at the 2
weeks time-point post-PRK. Here, we show that Rosiglitazone’s
ability to reduce residual HOAs is maintained well beyond the 2
weeks post-operative period during which the drug was adminis-
tered. Overall, whether the emmetropization effect of Rosiglita-
zone is truly permanent remains to be determined. Clearly, this
drug is not optimal for use following laser refractive surgery, where
refractive changes are intended and desirable. Instead, Rosiglita-
zone would most likely be highly beneficial in situations where a
[pathological] corneal wound caused unwanted changes in
refractive power and/or higher order aberrations, and where the
patient’s visual recovery would actually depend on near-total
restoration of corneal thickness as well as refractive power.
Putative Mechanisms of Rosiglitazone’s Anti-fibrotic
Actions in the Cornea
Like Pioglitazone, Troglitazone and Ciglitazone, Rosiglitazone
belongs to the Thiazolidinedione (TZD) class of drugs, and has
traditionally been used as an oral hypoglycemic agent for the
treatment of Type II diabetes [89,90]. While TZDs are effective
insulin-sensitizers [91], they can also act as anti-inflammatory
agents in such conditions as rheumatoid arthritis, inflammatory
bowel disease, ischemia-reperfusion injury and experimental
encephalomyelitis [38,39,92,93,94]. Finally, TZDs have been
shown to act as anti-fibrotics in both lung [44] and corneal tissue
[53] in vitro. However, while their ability to control lipid
metabolism is PPARc-dependent [46,47,48], accumulating evi-
dence, suggests largely PPARc-independent, off-target effects for
controlling fibrosis. These could include impact on SMAD,
Integrin/FAK, as well as p38/MAPK pathways, all of which
can contribute to fibrosis under different circumstances (see recent
review [95]). Ongoing cell culture experiments in our laboratory
are examining the effects of PPARc ligands on SMAD2/3
phosphorylation and nuclear translocation, as well as on
phosphorylation and activity of Rho, Erk, JNK, p38 and Akt –
all of which are known to be activated by TGFb receptor binding
in fibroblasts.
In vivo, stromal keratocytes are unlikely to be the only cells
impacted by Rosiglitazone – both epithelial and inflammatory cells
play important roles in corneal wound healing [96]. Thus, it is
possible that some of the beneficial effect of Rosiglitazone in
corneal wound healing involved direct action on epithelial and/or
inflammatory cells [97,98], and these processes may include both
PPARc-dependent and -independent signaling. Indeed, PPARc-
dependent signaling is already known to play a role in
inflammation control (reviewed in [99]). Further studies are
needed to examine the relative contribution of immune cell
inhibition by this TZD to the anti-fibrotic effects observed in the
present animal model. Similarly, the mechanisms of action of
Rosiglitazone in epithelial cells need to be clarified. Diversity of
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the same cell type, underscores a necessity to systematically detail
their behavior and mechanisms of action in both damaged and un-
operated, healthy corneas. Only with this knowledge, will we be
able to properly control topical administration of Rosiglitazone
and other TZDs and to optimize treatment outcomes in
preparation for clinical implementation of this work.
In conclusion, Rosiglitazone inhibited the appearance of
aSMA-positive cells in the wound area of excimer-laser-ablated
cat corneas, but allowed rapid stromal and epithelial re-thickening
to occur. Three months later, the result was a cornea whose total
thickness had returned to near-normal, whose refraction had
returned to near-emmetropia, and whose clarity had returned to
normal. Clear differences emerged between Rosiglitazone and
anti-TGFb treatment following laser ablation in our cat model,
confirming the hypothesis that Rosiglitazone likely exerted its anti-
fibrotic actions in the cornea via pathways downstream of TGFb
signaling. Thus, it appears that manipulating pathways down-
stream of TGFb signaling could be more beneficial in healing a
corneal wound than neutralizing TGFb.
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